Vanda Pharmaceuticals (FRA:VM4) Total Assets : €600.5 Mil (As of Mar. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals Total Assets?

Vanda Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 was €600.5 Mil.

During the past 12 months, Vanda Pharmaceuticals's average Total Assets Growth Rate was 80.80% per year. During the past 3 years, the average Total Assets Growth Rate was 16.20% per year. During the past 5 years, the average Total Assets Growth Rate was 19.10% per year. During the past 10 years, the average Total Assets Growth Rate was 26.40% per year.

During the past 13 years, Vanda Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 113.30%. The lowest was -9.70%. And the median was 16.20%.

Total Assets is connected with ROA %. Vanda Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2024 was -2.55%. Total Assets is also linked to Revenue through Asset Turnover. Vanda Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 was 0.07.

Vanda Pharmaceuticals Total Assets Historical Data

The historical data trend for Vanda Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals Total Assets Chart

Vanda Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

435.37

438.50

525.51

598.73

594.62

Vanda Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															601.99	592.27	601.18	594.62	600.47

Vanda Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Vanda Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	499.682	+	94.937
	=	594.6

Vanda Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	500.475	+	99.992
	=	600.5

Vanda Pharmaceuticals (FRA:VM4) Total Assets Explanation

Total Assets is connected with ROA %.

Vanda Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-15.256	/	( (594.619	+	600.467)	/ 2 )
	=	-15.256	/	597.543
	=	-2.55 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Vanda Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	43.665	/	( (594.619	+	600.467)	/ 2 )
=	43.665	/	597.543
=	0.07

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Vanda Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Vanda Pharmaceuticals (FRA:VM4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (FRA:VM4) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

VNDA:USA VM4:Germany

Address

2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037

Website

https://www.vandapharma.com

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include VHX-896 and ASO Molecules. The majority of revenue is derived from HETLIOZ product sales.

Vanda Pharmaceuticals (FRA:VM4) Headlines

No Headlines